Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > July 20, 2020
Daily News
July 20, 2020
- Kadcyla, Keytruda, Imfinzi in Line for Label Expansion in August
July 20, 2020
- Expand Self-Medication Tax Break and Make It Permanent: Industry Groups
July 20, 2020
- National CV Center Spin-Off Developing Oligonucleotide Therapy for Dyslipidemia, Eyes 1st Trial in FY2022
July 20, 2020
- 2020 Policy Blueprint Restresses Efforts on COVID-19 Meds/Vaccines; Drug Price Survey Up for Discussion on July 22
July 20, 2020
- Trade Group Urges Drug Makers to Fully Provide Info on Stock-Outs, Supply Curbs
July 20, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…